Konstantinos Xynos Sells 15,881 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPLGet Free Report) insider Konstantinos Xynos sold 15,881 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $7.50, for a total value of $119,107.50. Following the completion of the transaction, the insider now owns 117,131 shares in the company, valued at approximately $878,482.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Replimune Group Stock Up 13.9 %

Shares of NASDAQ REPL opened at $9.00 on Tuesday. The business has a 50-day moving average price of $6.51 and a 200 day moving average price of $7.69. The stock has a market cap of $552.78 million, a PE ratio of -2.78 and a beta of 1.16. The company has a quick ratio of 10.72, a current ratio of 10.72 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $24.81.

Replimune Group (NASDAQ:REPLGet Free Report) last issued its quarterly earnings data on Thursday, May 16th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.04. Equities research analysts forecast that Replimune Group, Inc. will post -3.25 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright upped their price target on Replimune Group from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday. Wedbush restated an “outperform” rating and issued a $16.00 target price on shares of Replimune Group in a report on Thursday, June 6th. Finally, Barclays increased their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Friday.

Read Our Latest Analysis on REPL

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the business. Alps Advisors Inc. raised its stake in Replimune Group by 2.6% during the 3rd quarter. Alps Advisors Inc. now owns 43,550 shares of the company’s stock valued at $745,000 after acquiring an additional 1,083 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Replimune Group by 6.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 32,311 shares of the company’s stock worth $272,000 after purchasing an additional 1,844 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Replimune Group by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock worth $66,000 after purchasing an additional 1,988 shares during the period. Principal Financial Group Inc. grew its position in Replimune Group by 17.2% in the 3rd quarter. Principal Financial Group Inc. now owns 14,748 shares of the company’s stock valued at $252,000 after buying an additional 2,165 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Replimune Group by 236.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock valued at $35,000 after buying an additional 2,958 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

(Get Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

See Also

Insider Buying and Selling by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.